164 related articles for article (PubMed ID: 36818179)
1. The impact of thyroid imaging reporting and data system on the management of Bethesda III thyroid nodules.
Alqahtani SM; Al-Sobhi SS; Alturiqy MA; Alsalloum RI; Al-Hindi HN
J Taibah Univ Med Sci; 2023 Jun; 18(3):506-511. PubMed ID: 36818179
[TBL] [Abstract][Full Text] [Related]
2. Clinico-cytopathological subcategorization in thyroid nodules of atypia of undetermined significance/follicular lesion of undetermined significance using the TIRADS and Bethesda classifications.
Babajani A; Rahmani S; Raoufi M; Eidgahi ES; Dastjerdi AV; Behfarnia P; Khalili S; Moghaddam NA
Front Endocrinol (Lausanne); 2023; 14():1135196. PubMed ID: 37313444
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the American College of Radiology Thyroid Imaging, Reporting and Data System (Thyroid imaging reporting) scoring in thyroid Bethesda category on atypia and follicular lesion of uncertain significance patients.
Catal O; Ozer B; Sit M; Yazgi H
Rev Assoc Med Bras (1992); 2021 Apr; 67(4):511-515. PubMed ID: 34495053
[TBL] [Abstract][Full Text] [Related]
4. Does a higher American College of Radiology Thyroid Imaging Reporting and Data System (ACR TI-RADS) score forecast an increased risk of malignancy? A correlation study of ACR TI-RADS with FNA cytology in the evaluation of thyroid nodules.
Modi L; Sun W; Shafizadeh N; Negron R; Yee-Chang M; Zhou F; Simsir A; Sheth S; Brandler TC
Cancer Cytopathol; 2020 Jul; 128(7):470-481. PubMed ID: 32078249
[TBL] [Abstract][Full Text] [Related]
5. Risk Stratification of Thyroid Nodules with Bethesda III Category: The Experience of a Territorial Healthcare Hospital.
Al Dawish M; Alwin Robert A; Al Shehri K; Hawsawi S; Mujammami M; Al Basha IA; Alrasheed M; Asiri S; Alzouman M; Alkharashi E
Cureus; 2020 May; 12(5):e8202. PubMed ID: 32455091
[TBL] [Abstract][Full Text] [Related]
6. USING THE ATA AND ACR TI-RADS SONOGRAPHIC CLASSIFICATIONS AS ADJUNCTIVE PREDICTORS OF MALIGNANCY FOR INDETERMINATE THYROID NODULES.
Ahmadi S; Herbst R; Oyekunle T; Jiang X'; Strickland K; Roman S; Sosa JA
Endocr Pract; 2019 Sep; 25(9):908-917. PubMed ID: 31170369
[No Abstract] [Full Text] [Related]
7. Thyroid cytology-nuclear versus architectural atypia within the "Atypia of undetermined significance/follicular lesion of undetermined significance" Bethesda category have significantly different rates of malignancy.
Gan TR; Nga ME; Lum JH; Wong WM; Tan WB; Parameswaran R; Ngiam KY
Cancer Cytopathol; 2017 Apr; 125(4):245-256. PubMed ID: 28192631
[TBL] [Abstract][Full Text] [Related]
8. Performance of ACR TI-RADS and the Bethesda System in Predicting Risk of Malignancy in Thyroid Nodules at a Large Children's Hospital and a Comprehensive Review of the Pediatric Literature.
Hess JR; Van Tassel DC; Runyan CE; Morrison Z; Walsh AM; Schafernak KT
Cancers (Basel); 2023 Aug; 15(15):. PubMed ID: 37568791
[TBL] [Abstract][Full Text] [Related]
9. Risk of malignancy according to sub-classification of the atypia of undetermined significance or follicular lesion of undetermined significance (AUS/FLUS) category in the Bethesda system for reporting thyroid cytopathology.
Kim SJ; Roh J; Baek JH; Hong SJ; Shong YK; Kim WB; Song DE
Cytopathology; 2017 Feb; 28(1):65-73. PubMed ID: 27245883
[TBL] [Abstract][Full Text] [Related]
10. ACR TI-RADS and ATA US scores are helpful for the management of thyroid nodules with indeterminate cytology.
Barbosa TLM; Junior COM; Graf H; Cavalvanti T; Trippia MA; da Silveira Ugino RT; de Oliveira GL; Granella VH; de Carvalho GA
BMC Endocr Disord; 2019 Oct; 19(1):112. PubMed ID: 31664992
[TBL] [Abstract][Full Text] [Related]
11. Thyroid cytology in Pakistan: An institutional audit of the atypia of undetermined significance/follicular lesion of undetermined significance category.
Fatima S; Qureshi R; Imran S; Idrees R; Ahmad Z; Kayani N; Ahmed A
Cytopathology; 2021 Mar; 32(2):205-210. PubMed ID: 33098589
[TBL] [Abstract][Full Text] [Related]
12. High risk of malignancy in cases with atypia of undetermined significance on fine needle aspiration of thyroid nodules even after exclusion of NIFTP.
Özkara SK; Bayrak BY; Turan G
Diagn Cytopathol; 2020 Nov; 48(11):986-997. PubMed ID: 32745375
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of ACR TI-RADS cytologically indeterminate thyroid nodules and molecular profiles: a single-institutional experience.
Belovarac B; Zhou F; Modi L; Sun W; Shafizadeh N; Negron R; Yee-Chang M; Szeto O; Simsir A; Sheth S; Brandler TC
J Am Soc Cytopathol; 2022; 11(3):165-172. PubMed ID: 35181254
[TBL] [Abstract][Full Text] [Related]
14. Thyroid nodules with atypia or follicular lesions of undetermined significance (Bethesda Category III): importance of ultrasonography and cytological subcategory.
Rosario PW
Thyroid; 2014 Jul; 24(7):1115-20. PubMed ID: 24684285
[TBL] [Abstract][Full Text] [Related]
15. Risk Stratification of Thyroid Nodules With Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance (AUS/FLUS) Cytology Using Ultrasonography Patterns Defined by the 2015 ATA Guidelines.
Lee JH; Han K; Kim EK; Moon HJ; Yoon JH; Park VY; Kwak JY
Ann Otol Rhinol Laryngol; 2017 Sep; 126(9):625-633. PubMed ID: 28719972
[TBL] [Abstract][Full Text] [Related]
16. Malignancy Rates of Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance (AUS/FLUS) Cases: A Tertiary Center Study.
Erdogan-Durmus S; Balta H; Demirtas R; Kurt A
Acta Endocrinol (Buchar); 2021; 17(1):77-82. PubMed ID: 34539913
[TBL] [Abstract][Full Text] [Related]
17. Malignancy rate in thyroid nodules classified as Bethesda category III (AUS/FLUS).
Ho AS; Sarti EE; Jain KS; Wang H; Nixon IJ; Shaha AR; Shah JP; Kraus DH; Ghossein R; Fish SA; Wong RJ; Lin O; Morris LG
Thyroid; 2014 May; 24(5):832-9. PubMed ID: 24341462
[TBL] [Abstract][Full Text] [Related]
18. Subclassification of the Bethesda Category III (AUS/FLUS): A study of thyroid FNA cytology based on ThinPrep slides from the National Cancer Center in China.
Zhao H; Guo H; Zhao L; Cao J; Sun Y; Wang C; Zhang Z
Cancer Cytopathol; 2021 Aug; 129(8):642-648. PubMed ID: 34139103
[TBL] [Abstract][Full Text] [Related]
19. Malignancy rate of Bethesda category III thyroid nodules according to ultrasound risk stratification system and cytological subtype.
Yoo WS; Ahn HY; Ahn HS; Chung YJ; Kim HS; Cho BY; Seo M; Moon JH; Park YJ
Medicine (Baltimore); 2020 Jan; 99(2):e18780. PubMed ID: 31914102
[TBL] [Abstract][Full Text] [Related]
20.
Zhu Y; Wu H; Huang B; Shen X; Cai G; Gu X
Gland Surg; 2020 Oct; 9(5):1674-1684. PubMed ID: 33224845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
